The University of Chicago Header Logo

Connection

Peter Riedell to Lymphoma, Large B-Cell, Diffuse

Back to Details
This is a "connection" page, showing publications Peter Riedell has written about Lymphoma, Large B-Cell, Diffuse.
Peter Riedell
Connection Strength
3.934
Lymphoma, Large B-Cell, Diffuse
  1. Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas. Transplant Cell Ther. 2022 10; 28(10):669-676.
    View in: PubMed
    Score: 0.816
  2. Should We Use Cell of Origin and Dual-protein Expression in Treating DLBCL? Clin Lymphoma Myeloma Leuk. 2018 02; 18(2):91-97.
    View in: PubMed
    Score: 0.595
  3. Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome. Blood Adv. 2023 09 12; 7(17):4765-4772.
    View in: PubMed
    Score: 0.221
  4. Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions. Blood Adv. 2023 08 22; 7(16):4528-4538.
    View in: PubMed
    Score: 0.220
  5. Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy. Blood Adv. 2023 07 11; 7(13):3192-3198.
    View in: PubMed
    Score: 0.218
  6. Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: phase 1b PORTIA study results. Blood Adv. 2023 06 13; 7(11):2283-2286.
    View in: PubMed
    Score: 0.217
  7. Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. N Engl J Med. 2023 Jul 13; 389(2):148-157.
    View in: PubMed
    Score: 0.217
  8. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol. 2022 08; 23(8):1066-1077.
    View in: PubMed
    Score: 0.204
  9. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat Med. 2022 04; 28(4):735-742.
    View in: PubMed
    Score: 0.200
  10. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med. 2022 02 17; 386(7):640-654.
    View in: PubMed
    Score: 0.196
  11. Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma. Blood. 2021 06 17; 137(24):3454-3459.
    View in: PubMed
    Score: 0.189
  12. Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapy. Am J Hematol. 2016 10; 91(10):1002-7.
    View in: PubMed
    Score: 0.135
  13. Longitudinal Body Composition Changes in Diffuse Large B-cell Lymphoma Survivors: A Retrospective Cohort Study of United States Veterans. J Natl Cancer Inst. 2016 11; 108(11).
    View in: PubMed
    Score: 0.134
  14. Incidence of venous thromboembolism in patients with non-Hodgkin lymphoma. Thromb Res. 2016 Jul; 143:86-90.
    View in: PubMed
    Score: 0.133
  15. Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma. J Geriatr Oncol. 2015 May; 6(3):211-8.
    View in: PubMed
    Score: 0.121
  16. Impact of body mass index on incidence of febrile neutropenia and treatment-related mortality in United States veterans with diffuse large B-cell lymphoma receiving rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone. Br J Haematol. 2014 Dec; 167(5):699-702.
    View in: PubMed
    Score: 0.117
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.